Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) | RFA CA 21 004

Opportunity Information: Apply for RFA CA 21 004

The Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) funding opportunity (RFA-CA-21-004) is a National Cancer Institute (NCI), National Institutes of Health (NIH) grant solicitation within the broader Innovative Molecular Analysis Technologies (IMAT) Program. It is designed to support exploratory, later-stage technology development projects that are past the earliest proof-of-concept hurdles but are not yet mature enough for broad, confident uptake by the wider research community. In practical terms, applicants are expected to already have credible preliminary data showing the core idea works and that key feasibility gaps have been addressed, while still needing additional development, optimization, and rigorous validation to demonstrate reliability, performance, and usefulness in real cancer research settings.

The scientific focus is on emerging technologies that provide genuinely new or significantly improved ways to target, probe, or assess molecular and cellular features central to cancer biology. The FOA is specifically oriented toward tools and methods that improve molecular and/or cellular characterization of cancer, which can include innovations relevant to basic research as well as clinically oriented research, as long as the work does not involve a clinical trial. The intended impact is broad: funded technologies should have clear potential to accelerate or strengthen research across cancer biology, early detection and screening, clinical diagnosis, treatment and therapeutic decision-making, cancer control, epidemiology, and efforts that address cancer health disparities. While technologies may be built to be widely applicable across tumor types or research contexts, the proposal must stay centered on advancing the measurement or analysis capabilities themselves, rather than using an established tool to answer a new biological question.

A key boundary in this announcement is what it will not support. Projects are not appropriate if the main novelty lies in the cancer target, specimen type, patient population, or biological hypothesis, while the technology being used is essentially existing or only incrementally adapted. In other words, this is not a mechanism for primarily biological discovery or clinical question-driven studies that happen to use a known platform. The technical innovation and its validation are the core of what will be reviewed, and proposals that are better described as applications of existing technologies (even to important cancer problems) are considered nonresponsive and will not be reviewed.

The award mechanism is an R33 grant, which generally aligns with advanced developmental work where there is already evidence the approach is feasible, and the next step is to demonstrate robustness, reproducibility, and utility through careful validation. The FOA explicitly states that clinical trials are not allowed under this opportunity, signaling that the supported work should remain at the technology development and validation stage rather than testing interventions or clinical outcomes in trial settings.

Eligibility is broad and includes many organization types that commonly participate in NIH funding, including state, county, and local governments; public and state-controlled institutions of higher education; private institutions of higher education; independent school districts; special district governments; federally recognized Native American tribal governments and other tribal organizations; public housing authorities and Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (excluding institutions of higher education in those categories as specified); for-profit organizations other than small businesses; and small businesses. The announcement also highlights additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and even non-U.S. entities (foreign organizations). This inclusive eligibility language fits the FOA’s interest in technologies that can strengthen cancer research broadly, including work that may help reduce disparities.

Administratively, the opportunity is categorized as discretionary funding and uses the grant funding instrument, with a health and education activity category listed under CFDA 93.394. The original closing date provided is September 28, 2021, and the opportunity record creation date is November 20, 2020. An explicit award ceiling is not listed in the provided source data.

Overall, the FOA is best read as a targeted push to move promising, next-generation molecular and cellular analysis technologies from “working in principle” to “validated and ready for others to adopt.” Competitive projects would typically emphasize measurable performance improvements, clear validation plans, reproducibility, comparisons to current best-in-class methods where appropriate, and a credible pathway to dissemination and community use, all while keeping the central contribution squarely on the technology itself and its ability to advance cancer research.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394.
• This funding opportunity was created on 2020-11-20.
• Applicants must submit their applications by 2021-09-28. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA CA 21 004

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: